Discovery 670 pro

LN mapping was performed 3–5 h after intracervical injection of ≈ 200 MBq [^99mTc]Tc-Nanocolloide at the 3, 6, 9, and 12 o’clock positions. Imaging was performed with a hybrid SPECT/CT scanner (Discovery 670 Pro^®, GE Healthcare, Chicago, IL, USA), as described previously [16 (link)]. An SLN was defined as focal activity enrichment in SPECT in a plausible anatomical region.

Patients were scanned on a hybrid SPECT/CT device (Discovery 670 Pro, GE Healthcare, Chicago, US), three hours after injection of 8–10 MBq/Kg of Tc-99M-DPD (CIS Bio, Berlin, Germany). To minimize artifacts caused by the presence of radioactive urine in the excretory system, patients were asked to drink at least 1000 ml of water during the uptake time and to void immediately before the scan.
The acquisition comprised a whole-body planar scan, followed by a whole-body SPECT/CT, from vertex up to the distal femoral epiphyses, obtained by reconstructing and fusing three sequential fields of view (Xeleris 3, GE Healthcare, Chicago, USA). SPECT acquisition was carried out with the two camera heads in H-Mode; parameters for each field of view were as follows: energy window 140.5 ± 10%, angular step 6°, time per step 15′′. The transaxial field of view and pixel size of the reconstructed SPECT images were 54 cm and 5 × 5 mm, respectively, with a matrix size of 128 × 128. SPECT raw data were reconstructed using OSEM iterative protocol (2 iterations, 10 subsets).
The 16-detector row, helical CT scanner used a gantry rotation speed of 0.8 s and a table speed of 20 mm per rotation, with a 120 kV voltage and 10–80 mA current. A dose modulation system (OptiDose, GE Healthcare, Chicago, US) was applied to minimize total exposure according to the patient's size. No contrast medium was injected.